CALL FOR PAPERS
Early Detection and Minimal Residual Disease Call for Papers
PLOS MEDICINE
Part of a PLOS Medicine Special Issue: Cancer Advances: Clinically Applicable Insights into Early Detection and Minimal Residual Disease. PLOS Medicine is committed to publishing the highest caliber medical research and getting your work in front of the medical community. Deadline March 15, 2021.
Research estimates that the number of cancer cases has reached 17.2 million with 8.9 million of those cases resulting in death. Our expert Guest Editors are eager to create this Special Issue with the aim of helping the cancer research community to reduce the global mortality rate and develop areas in new technologies for early tumor detection, such as the detection of minimal residual disease.
Our panel of Guest Editors will consider high-quality translational and clinical studies, and prioritize research articles likely to inform clinical advances for patients.
- Translational and clinical research
- Cancer research
- Cancer prognosis
- Cancer metastasis
- Cancer detection
- Biomarkers
- DNA sequencing
- Circulating tumor DNA
Charles Swanton
The Francis Crick Institute, United Kingdom
Sarah Jane Dawson
Peter MacCallum Cancer Centre, Australia
Chris Abbosh
University College London, United Kingdom
Over 320 PLOS Medicine papers have been published on early detection and minimal residual disease.
43,000+
Citations of PLOS Medicine Early detection papers (135 per paper)
60
Days to First Decision on average
PLOS Medicine publishes impactful articles on medical, clinical, environmental, social and political determinants of health and associated outcomes. Submissions should directly and substantially inform clinical practice or health policy, and be relevant to a broad international audience.
Email questions to plosmedicine@plos.org
Submit your paper to PLOS Medicine to be considered for this Collection.
Mention the Early Detection and Minimal Residual Disease Special Issue in your cover letter. The paired Special Issue will publish Spring 2021.